PremiumThe FlyKymera Therapeutics price target raised to $60 from $54 at H.C. Wainwright Kymera Therapeutics price target raised to $59 from $55 at BTIG Kymera Therapeutics price target lowered to $53 from $57 at Wells Fargo PremiumThe FlyMorning Movers: General Mills dips following fourth quarter report Kymera Therapeutics Partners with Gilead for Oncology Treatment Kymera Therapeutics Advances KT-485 in Sanofi Collaboration PremiumThe FlyKymera Therapeutics price target raised to $60 from $52 at Guggenheim Kymera Therapeutics’ KT-621 Shows Promising Trial Results, Supporting Buy Rating Promising Potential of Kymera Therapeutics’ KT-621: Strong Therapeutic Effect and Buy Rating Affirmed 
